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Research eﬀorts were focused on genetic alterations in epithelial cancer cells. Epithelial-stromal interactions play a crucial role
in cancer initiation, progression, invasion, angiogenesis, and metastasis; however, the active role of stroma in human breast
tumorigenesis in relation to estrogen receptor (ER) status of epithelial cells has not been explored. Using proteomics and
biochemical approaches, we identiﬁed two stromal proteins in ER-positive and ER-negative human breast cancer tissues that
may aﬀect malignant transformation in breast cancer. Two putative biomarkers, T-cell receptor alpha (TCR-α) and zinc ﬁnger
and BRCA1-interacting protein with a KRAB domain (ZBRK1), were detected in leukocytes of ER-positive and endothelial cells
of ER-negative tissues, respectively. Our data suggest an immunosuppressive role of leukocytes in invasive breast tumors, propose
a multifunctional nature of ZBRK1 in estrogen receptor regulation and angiogenesis, and demonstrate the aggressiveness of ER-
negative human breast carcinomas. This research project may identify new stromal drug targets for the treatment of breast cancer
patients.
1.Introduction
It is proposed that stromal cells surrounding DCIS and inva-
sive ductal carcinoma are heterogeneous undergoing geno-
typic and phenotypic alterations that could have occurred
prior to or concurrent with alterations in adjacent cancerous
epithelial cells [1]. As tumor progresses, it is accompa-
nied by proliferation of ﬁbroblasts, lymphocyte inﬁltra-
tion, and angiogenesis in surrounding stromal tissues [2].
Whether these stromal changes reﬂect a passive or active
reaction to the malignant transformation has not been
explored in suﬃcient depth. The concept of epithelial-
stromal interactions and their contributions to the devel-
opment and progression of mammary neoplasia has been
proposed, but these previous hypotheses emphasize stromal
“reactions” to the malignant transformation of epithelial
cells [3]. However, ongoing eﬀorts are challenging the old
paradigm that considers microenvironmental factors as a
reactive responder rather than an interactive component.
Several studies have conﬁrmed that stromal cells, including
ﬁbroblasts, leukocytes, and endothelial cells, inﬂuence the
growth, diﬀerentiation, and invasive behavior of normal
mammary epithelial cells and breast carcinomas [4–7].
Recently, microenvironmental factors of mesenchymal stem
cells were found to promote breast cancer metastasis in mice
[8]. Transforming growth factor β (TGF-β), one of the best
studied extracellular cytokine, was shown to modulate the
growth and oncogenesis of adjacent epithelia [9]. Moreover,
studies using ionizing radiation alter the stroma in a way
that promoted neoplastic potential [10]. Tumor-associated
macrophages have been shown to promote angiogenesis,
invasion, and metastasis [11, 12]. Inﬂammation, which is2 Journal of Biomedicine and Biotechnology
primarily a stromal reaction, has been linked to cancer risk
[13]. A noteworthy study reveals distinctive gene expression
pattern with prominent expression of tumor promotion-
associated genes in breast cancer-derived stromal ﬁbroblasts
as compared to normal ones [14]. These studies underscore
the stromal-epithelial interface as a critical mediator of
oncogenic potential. While stromal cells are inﬂuenced by
the adjacent epithelium via paracrine mechanisms, they are
notjustrespondingtothesestimulibutalsoactivelyaﬀecting
the fate of adjacent epithelium. These data demonstrate that
targeting the tumor stromal microenvironment will be a
reasonable new therapeutic strategy.
Depriving tumor cells of an essential structural and
functional support by inhibiting tumor stroma may result in
amoreeﬃcienttumorregressionandtreatment.Morerecent
genomic characterization of tumor microenvironment was
done by the puriﬁcation of all major cell types from
normal breast tissue, DCIS, and invasive carcinomas [3].
However, the active role of stromal component in human
breast tumor development and progression in relation to
the estrogen receptor status of epithelial tumor cells has not
been explored. Here, we investigate the proteomic alterations
of stromal cells adjacent to estrogen receptor positive or
estrogen receptor negative epithelial cells that may serve as
biomarkers of malignant transformation.
2.MaterialsandMethods
2.1. Tissue Preparation. Freshly frozen breast tumor speci-
mens were collected from Southern Division of the Coop-
erative Human Tissue Network. Based on the pathological
diagnosis of each tissue sample, six ER-positive and four ER-
negative tissues were selected. Collectively, ER-positive and
ER-negative specimens were minced in liquid nitrogen and
processed as described by Shipitsin et al. [1]
2.2. Cell Separation
2.2.1. Epithelial Cells. To isolate epithelial cells from the total
cell fraction: 50μL (or 10–20μL for small tumor tissue) of
prewashed BerEP4 beads were added to the cells (Dynal
cat no. 161.02), incubated for 8min on ice with occasional
“ﬂicking” of the tube then diluted to 3–5mL volume with
PBE. Cells were captured on magnet for 2min. Captured
fraction contained the luminal epithelial cells. Bound cells
were washed with 3 × 200μL PBE and then immediately
frozen on dry ice. Supernatant was placed into a centrifuge
tube and magnetic capturing was repeated to ensure that all
bead bound cells are removed.
2.2.2. Leukocytes. 100 to 200μL of prewashed Dynabeads
(equal mix of CD45 cat no. 111.53D and CD15 cat no.
111.37D from Invitrogen) was added to the cell suspension.
Cells were then incubated for 20min at 4◦C with gentle
tilting and rotation followed by magnetic separation for
2min. Leukocyte bound cells were washed 3 times by
resuspending in PBE buﬀer to remove contaminating cells
followed by incubation on dry ice. Unbound cells were
transferred to a new centrifuge tube, and magnetic capturing
was repeated to ensure that all bead bound cells are removed.
Unbound cells and ﬁrst wash were combined and collected
by centrifugation.
2.2.3. Endothelial Cells. Collected cells were incubated with
100μL prewashed CD31 beads (cat no. 111.55D Invitrogen)
for20minat4◦Cwithgentletiltingandrotation.Endothelial
bound cells were washed 3 times by resuspending in PBE
followed by immediate freezing on dry ice.
2.2.4. Myoﬁbroblasts. Cells were collected by centrifugation
and resuspended in 500–1000μL PBE followed by the
addition of 50μL of prewashed/bound CD10 beads (bind
20μL biotinylated antibody CD10 (Cat no. 13-0108-82,
eBioscience, San Diego, Calif, USA) to 50μLb e a d sf r o m
CELLection Biotin Binder Kit (Cat no. 115.33D, Invitrogen,
Carlsbad, Calif, USA) in 100μL PBE and incubation on
ice for 1 hour with occasional “ﬂicking” of the tube.
Myoﬁbroblasts were then captured. Bound cells were washed
with 3 × 200μL PBE then immediately frozen on dry ice.
2.3.ProteinExtractionandQuantiﬁcation. Cellswerelysedin
30mM Tris, 7M Urea, 4% CHAPS, with protease inhibitors,
followed by vortexing for 1 hour, then centrifugation for
15min at 15,000 ×g. Supernatants were collected and
quantiﬁed as described previously [15]. Brieﬂy, microplate
bicinchoninicacid(BCA)proteinassaykit(Pierce,Rockford,
Ill, USA) was used to determine the protein concentration
using bovine serum albumin as a standard according to
manufacturer’s instructions. A triplicate of each sample was
utilized, and the mean absorbance was taken to calculate the
concentration of the protein using the standard curve.
2.4. Two-Dimensional Gel Electrophoresis. A total of 50μg
of proteins were vacuum-dried and reconstituted in 200μL
of rehydration buﬀer (30mM Tris, 7M Urea, 4% CHAPS,
and 50mM DTT). Isoelectric focusing was performed using
Immobilized pH Gradient (IPG) strips, pH 4 to 7 (Bio-Rad).
This was followed by rehydration of the strips in 375mM
Tris-HCLpH8.8,6Murea,2%SDS,and2%DTTfor15min
followed by a second equilibration in 375mM Tris-HCL pH
8.8, 6M urea, 2% SDS, and 2% iodoacetamide. The 2nd
dimension of the separation was performed by placing the
strips onto a 10% polyacrylamide gel as described previously
[16]. Gels were electrophoresed at 50V for 30min then at
100V till the end of separation. The cathode buﬀer consisted
of 0.1M Tricine, 0.1M Tris-HCl, pH 8.2, and 0.1% SDS,
whereas the anode buﬀer was composed of 0.2M Tris-HCl,
pH 8.9. Gels were ﬁxed in 40% ethanol and 10% acetic acid
and stained with SYPRO Ruby (Bio-Rad) for 3 hours at
room temperature as described previously [17]. Gels were
destained in 10% methanol and 7% acetic acid to decrease
background staining followed by washing 3 times in ddH2O.
Typhoon 9410 Scanning Systems (GE Healthcare) was used
to scan the gels. The excitation wavelength was 457nm, and
the signals were detected at 550V.Journal of Biomedicine and Biotechnology 3
2.5. Trypsin Digestion and NanoLC-Q-TOF-MS/MS. Gel
pieces were transferred into a 96-well ZiplateC18 (Cat no.
ZPC180010, Millipore, Bedford, Mass, USA). Protein diges-
tion and peptide recovery procedures were performed as
describedpreviously[18].Brieﬂy,Gelpiecesweredehydrated
by adding 200μL of acetonitrile to each well followed by 10-
minute incubation. Full vacuum was then applied to elute
the acetonitrile through the C18 resin forming the bottom of
the Ziplate. Gel pieces were then rehydrated by adding 15μL
of a 25mM ammonium bicarbonate containing 5ng/μLo f
modiﬁed trypsin. After overnight incubation at 37◦C, 8μL
of acetonitrile was added to the resin. After 12 minutes of
incubation, 100μL of 0.2% TFA ultrapure water solution
was added to each well and incubated for 30 minutes. The
96-well plate was then placed on a vacuum plate holder
to empty wells. A ﬁnal washing step was performed with
a 100μL of 0.2% TFA ultrapure water solution followed
by vacuum to empty wells. The Zipplate was then placed
upon a low retention 96-well “V” bottom plate (cat no.
2897, Corning Inc., Corning, NY, USA), and tryptic digests
were eluted by adding 8μL of acetonitrile followed by
centrifugation at 3000 ×g. The tryptic digest was then
vacuum-dried and reconstituted in solvent A (97.9% water,
2%Acetonitrile,0.1%Formicacid(v/v/v)).NanoLC/MS/MS
was performed using a Q-Star Elite (Applied Biosystems,
Foster City, Calif, USA) equipped with a nanoAcquity UPLC
system (Waters, Milford, Mass, USA). Sample separations
were performed using a 1.7μm nanoAcquity BEH130 C18
(100μm × 100mm) at a ﬂow rate of 400nL/min. Tryptic
digests were eluted using the following gradient: 100% of
Solvent A (97.9% water, 2% Acetonitrile, 0.1% Formic acid
(v/v/v)) for 1 hour; then from 100% solvent A to 100%
solvent B (2% water, 97.8% Acetonitrile, 0.1% Formic acid
(v/v/v)) in 2 hours; A 100% solvent B ﬂow was maintained
for 1 hour followed by a return to 100% of solvent A ﬂow
in 15min. Mass spectrometer settings were as follows: Ion
spray voltage 2300V, interface heater temperature 220◦C,
cone voltage 20V, and collision energy 8V.
2.6. Western Blotting. 25μg of proteins extracted from
diﬀerent cell types were reconstituted with SDS-PAGE buﬀer
and loaded onto a 10% polyacrylamide gel. The gel was
electrophoresed at 50V for 30min then at 100V till the
end of the separation as described previously [19]. Proteins
were then electroblotted onto a nitrocellulose membrane at
30V overnight. Following electroblotting, the membranes
were blocked with 5% BSA in TBST buﬀer. Western blot
analysis was then accomplished using 1μg/mL dilution
of ZBRK1 primary antibody (cat no. H00059348-D01P,
Novus Biologicals). This step was followed by incubation
with horseradish peroxidase-conjugated secondary antibody
against the appropriate species. Development of the bands
was accomplished by the addition of a 1 to 1 ratio of
Super Signal West Pico-Stable Peroxidase Solution and
Luminol/Enhancer Solution (Pierce, Rockford, Ill, USA) and
by using Kodak Scientiﬁc Imaging Film (cat no. 1651496,
Kodak), Fixer and Replenisher/Developer and Replenisher
(Kodak cat no. 1901859) according to manufacturer’s
instructions.
3. Results and Discussion
A common diagnostic feature of human breast cancer
progression from in situ to invasive tumor is the dissolution
of basement membrane and the gradual disappearance of
fully diﬀerentiated myoepithelial cell layer. The prevalence
of genetic changes and epigenetic modiﬁcations in all cell
types of the mammary gland suggest that tumor progres-
sion is a collaborative work among epithelial and stromal
cells challenging the old paradigm of epithelial cell-driven
tumorigenesis [3]. Polyak and Hu proposed two alternative
models of in situ to invasive carcinoma transition [20].
The authors purported that the “escape” and “release”
modelsmaynotbemutuallyexclusiveandmyoepithelialcells
together with inﬁltrating leukocytes and myoﬁbroblasts may
aﬀect the clonal evolution of tumor epithelial cells. Recent
studies support this combined model, as focal myoepithelial
cell layer disruptions were found to be associated with
higher leukocyte inﬁltration [21]. Tumor epithelial cells
overlying disrupted myoepithelial cells exhibited substantial
diﬀerences from other epithelial cells in the duct [22].
They were generally estrogen receptor negative with higher
proliferation rate, higher frequency of loss of heterozygosity
andhigherexpressionofinvasionandcellcycle-relatedgenes
[21, 23]. Despite these corroborating data of the eﬀect of
stromalcellsononcogenesis,ourknowledgeofthemolecular
mechanisms that govern the interactions among all cell
types to induce invasion is limited. Targeting tumor stromal
microenvironmentmayprovideapromisingopportunityfor
breast cancer prevention and treatment.
A high percentage of primary breast cancers are estrogen
receptor- (ER-) positive that generally have better prognosis
and are responsive to endocrine therapies [24, 25]. Unfor-
tunately, ER-negative breast cancers are more aggressive
and refractory to most therapies through a yet unknown
mechanism [26]. Therefore it is urgently needed to tailor
new treatments that target these cancers. Invasive breast
tumors display an ER-negative phenotype [22] that is often
considered to result from premalignant ER-positive breast
cancers by genetic alteration, epigenetic modiﬁcation [27]o r
ER proteasome degradation [28].
By virtue of the aggressiveness of ER-negative breast
cancers and their association with focally disrupted myoep-
ithelial cells, investigating the protein expression of ER-
negative and ER-positive surrounding microenvironments
may lead to identiﬁcation of important targets that will
enrich our understanding of malignant transformation in
human breast cancer. By comparing the protein proﬁles of
epithelial and stromal cells from estrogen receptor-negative
and estrogen receptor-positive breast carcinomas using nano
LC-Q-TOF-MS/MS, we were able to identify diﬀerential
protein signatures among the cell types isolated from the two
pathologies (Figure 1). Additionally, two putative biomark-
ers, T cell receptor alpha (TCR-α) and Zinc ﬁnger and
BRCA1-interacting protein with a KRAB domain (ZBRK1),
were identiﬁed.
The change in the protein proﬁle in the same cell type
isolated from ER-positive and ER-negative breast cancers
may explain the diﬀerence in behavior and aggressiveness4 Journal of Biomedicine and Biotechnology
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Figure 1: 2DE: two-dimensional gel electrophoresis (2DE) of epithelial cells (Epi), myoﬁbroblasts (Myo), leukocytes (leuk), and endothelial
cells (Endo) proteins separated from estrogen receptor-positive and estrogen receptor-negative breast cancer cells using antibody-bound
magnetic beads. First dimension was performed on a pH 4 to 7 isoelectric focusing gels and the second dimension was done utilizing 10%
polyacrylamide gels. Gels were stained by Sypro Ruby. Arrows point to identiﬁed proteins spots.
among the two adjacent cell clusters. Further analyses using
mass spectrometry lead to the identiﬁcation of two stromal
proteins. TCR-α w a sd e t e c t e di nl e u k o c y t e so fe s t r o g e n
receptor-positive breast cancer cells (Figure 2), and ZBRK1
was expressed in endothelial cells of estrogen receptor-
negative breast tissue (Figure 3). Western blot analysis of
ZBRK1 validates the higher level of expression of this protein
in endothelial cells of ER-negative tissues as compared to
their ER-positive counterparts (Figure 4). However, the lack
of TCR-α antibody speciﬁc to the identiﬁed peptide did not
allow further validation of the data.
Recent work expanded the historical view of cancer
immunosurveillance to incorporate the potential ability of
immune system to foster escape of primary tumors from
immune recognition and destruction [29]. The underlying
cellular and molecular mechanisms that govern the para-
doxical role of immune responses in cancer progression
are poorly understood. In 1863, the German pathologist
Rudolf Virchow was the ﬁrst to postulate a relationship
between tumor development and inﬂammation [30]. Var-
ious experimental studies have shown that macrophages
inﬁltrating neoplastic environment enhance development
of late-stage carcinomas and pulmonary metastases [31,
32] and are associated with unfavorable prognosis. It is
proclaimedthatimmuneresponsesareelicitedbyinteraction
of major histocompatability complex (MHC) with TCRJournal of Biomedicine and Biotechnology 5
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Figure 2: T cell receptor alpha spectra: T-cell receptor alpha was detected in the leukocytes of estrogen receptor-positive breast cancer not
in that of estrogen receptor negative. LC-Q-TOF MS/MS spectra of GITLSVRP peptide generated from the trypsin digestion of TCR-α.
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Figure 3: Zinc ﬁnger protein 350 spectra: Zinc ﬁnger protein 350 was identiﬁed in endothelial cells of estrogen receptor negative and not
in estrogen receptor-positive breast tissue. LC-Q-TOF MS/MS spectra of LQSESLVNR peptide generated from the trypsin digestion of ZNF
350.
composed of TCR-α and -β chains generated by somatic
rearrangements. In view of the fact that TCR-α is more
associated with peptides than TCR-β, it is suggested that
TCR-α is predominantly responsible for antigen recognition
[33]. The inability to detect TCR-α in leukocytes of ER-
negative breast samples (Figure 1) highlights the inability of
immune cells to recognize neoplastic cells that will bolster
their escape from host immunosurveillance mechanisms.
This result in part explains invasiveness of ER-negative tissue
and its association with high leukocytes inﬁltration.
ZBRK1, also called zinc ﬁnger 350 (ZNF350), binds to
target genes through its tandem zinc ﬁngers and physically
tethers with BRCA1 to form a transcriptional repression
complex that blunts transcription of many DNA damage
inducible genes (such as GADD45, Bax, Ki-67) that possess
ZBRK1 recognition loci and are commonly regulated by
BRCA1 [34]. Garcia et al. has shown altered expression of
ZBRK1 in primary human breast carcinomas; however, its
functional role in tumor progression is still tentative [35].
Our results reveal that ZBRK1 is expressed in endothelial
cells of estrogen receptor-negative tissues, thereby suggesting
a broader role of ZBRK1 in ER-α regulation as well as
vascularization (Figure 1). The implication of ZBRK1 in ER-
α regulation has not yet been reported; however, estrogen
receptor negative tissues are known to be associated with
reduced BRCA1, [36]. This complex relationship between
ZBRK1, BRCA1 and ER-α in breast carcinoma raises many
important issues that remain to be resolved. The expression
of ZBRK1 in endothelial cells proposes an angiogenic
function. One report by Furuta et al. demonstrated that
ZBRK1 reduces angiogenesis by forming a triad with BRCA1
and CtIP that impedes angiopoietin-1 (ANG1), expression
in mammary epithelial cells [37]. Disruption of this complex
increases ANG1 expression in epithelial cells resulting in
enhanced survival of endothelial cells and, therefore, exten-
sive vascularization. Our data shows pronounced expression
of ZBRK1 in endothelial cells rather than epithelial cells
suggesting that direct eﬀect on stroma vasculature. Whether
ZBRK1aﬀectsANG1orotherangiogenic factorsinendothe-
lial cells and whether it is in coordination with BRCA1 and
ER-α need further investigation.
In summary, the evidence for reciprocal interactions
between stromal and epithelial cells in malignant trans-
formation of benign tumor to invasive cancer is growing
steadily and can be incorporated to explain the conundrum
behind the neoplastic growth. Mammary stroma in ductal
carcinoma in situ (DCIS) and invasive ductal carcinoma may
represent an interactive component to the neoplastic process
rather than a mere reactive responder [38]. The active role
of stromal component in human breast tumor development
and progression in relation to the estrogen receptor status
of epithelial tumor cells was not explored previously. To
elucidate this role, we have isolated diﬀerent stromal cells
adjacent to ER-positive or ER-negative tumor epithelial cells.6 Journal of Biomedicine and Biotechnology
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Figure 4: (a) Western blot of ZBRK1in endothelial cells of estrogen
receptor negative (E−) and estrogen receptor positive (E+) breast
cancer tissues. (b) Bar diagram showing the relative intensity of
ZBRK1 in estrogen receptor negative (E−) and positive (E+) tissues
as compared the GAPDH control. ImageJ software was used for
densitometric analysis and error bars represents standard error.
The protein proﬁles of the various cells showed diﬀerential
protein signatures for each pathology suggesting potential
involvement of the tumor stromal microenvironment in
cancer progression. Furthermore, we were able to identify
two potential biomarkers, TCR-α and ZBRK1, which may
explain the aggressiveness of ER-negative tumors and may
be responsible for disruption of the myoepithelial cell layer
and its eventual disappearance during the progression of in
situ tumors to invasive cancers. Future research with a much
larger sample size to obtain statistically signiﬁcant results
and validate these ﬁndings quantitatively at transcriptional,
translational, and posttranslational levels is planned.
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